# High-Risk Non-Muscle-Invasive Bladder Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/high-risk-non-muscle-invasive-bladder-cancer

> 4 upcoming FDA catalysts in High-Risk Non-Muscle-Invasive Bladder Cancer: cretostimogene grenadenorepvec (CGON) on Mar to Jun 2027 (topline data readout); cretostimogene grenadenorepvec (CGON) on March 2027 (primary completion); KEYTRUDA® (pembrolizumab, MRK) on Jul to Oct 2028 (topline data readout); KEYTRUDA® (pembrolizumab, MRK) on July 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar to Jun 2027 | [Cretostimogene grenadenorepvec topline data readout](https://sec-api.dev/pdufa/cretostimogene-grenadenorepvec) | CGON | High-Risk Non-Muscle-Invasive Bladder Cancer | scheduled | "NCT06567743 (Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor CG Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06567743)) |
| March 2027 | [Cretostimogene grenadenorepvec primary completion](https://sec-api.dev/pdufa/cretostimogene-grenadenorepvec) | CGON | High-Risk Non-Muscle-Invasive Bladder Cancer | scheduled | "NCT06567743 (Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor CG Oncology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06567743)) |
| Jul to Oct 2028 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | High-risk Non-muscle Invasive Bladder Cancer | scheduled | "NCT03711032 (Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03711032)) |
| July 2028 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | High-risk Non-muscle Invasive Bladder Cancer | scheduled | "NCT03711032 (Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03711032)) |

## Drugs

- [Cretostimogene grenadenorepvec](https://sec-api.dev/pdufa/cretostimogene-grenadenorepvec) (CGON)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/high-risk-non-muscle-invasive-bladder-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "High-Risk Non-Muscle-Invasive Bladder Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/high-risk-non-muscle-invasive-bladder-cancer

```bibtex
@misc{secapidev_indications_high_risk_non_muscle_invasive_bladder_cancer_20261116,
  title        = {High-Risk Non-Muscle-Invasive Bladder Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/high-risk-non-muscle-invasive-bladder-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_high_risk_non_muscle_invasive_bladder_cancer_20261116","title":"High-Risk Non-Muscle-Invasive Bladder Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/high-risk-non-muscle-invasive-bladder-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
